Loading
A phase 2 trial of Palbociclib and Fulvestrant in HR-positive / HER2-negative breast cancer, run by Criterium, Inc., active and no longer recruiting.
DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE) is a phase 2 interventional study registered as NCT04567420 by Criterium, Inc., with 70 participants enrolled, started 2021-02-09 and due to reach its primary completion in 2027-12-31. Interventions recorded: Palbociclib, Fulvestrant and Adjuvant Therapy.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Palbociclib, Fulvestrant and the tag pipeline.
Shares Fulvestrant, HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares Palbociclib, Fulvestrant, HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares Palbociclib, Fulvestrant, HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares Palbociclib, Fulvestrant and the tag pipeline.
Shares Palbociclib, Fulvestrant, HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares Criterium, Fulvestrant and the tag pipeline.
Shares Palbociclib, Fulvestrant and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/